Exact Sciences Corporation

Equities

EXAS

US30063P1057

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-07-12 pm EDT 5-day change 1st Jan Change
46.36 USD +3.39% Intraday chart for Exact Sciences Corporation +4.02% -37.33%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Scotiabank Initiates Exact Sciences at Sector Outperform With $70 Price Target MT
BTIG Lowers Price Target on Exact Sciences to $70 From $80, Maintains Buy Rating MT
Exact Sciences Seeks Acquisitions CI
Transcript : Exact Sciences Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 03:20 PM
Biocartis NV Appoints Gina Wallar as Chief Business Officer CI
Transcript : Exact Sciences Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 11:00 AM
Transcript : Exact Sciences Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 12:40 PM
Exact Sciences Corporation Reaffirms Earnings Guidance for the Second-Quarter 2024 and Full-Year 2024 CI
Exact Sciences Corporation Announces Resignation of Everett Cunningham, Chief Commercial Officer, Effective on June 13, 2024 CI
Sector Update: Health Care Stocks Advance Pre-Bell Friday MT
Exact Sciences to Present New Data at Oncology Annual Meeting Confirming Prognostic Value of Breast Cancer Test MT
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations At Asco® CI
U.S. FDA advisers back approval for Guardant's cancer test RE
Exact Sciences Says Court Allows Patent Lawsuit Against Geneoscopy to Proceed MT
Transcript : Exact Sciences Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 01:40 PM
Exact Sciences Q1 Net Loss Widens, Revenue Increases; 2024 Revenue Outlook Maintained -- Shares Fall After Hours MT
Transcript : Exact Sciences Corporation, Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (EXAS) EXACT SCIENCES Reports Q1 Revenue $637.5M, vs. Street Est of $626.8M MT
Exact Sciences Corporation Reports Unaudited Consolidated Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2024 CI
Exact Sciences Corporation Maintains Revenue Guidance for the Full Year of 2024 CI
Exact Sciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Exact Sciences Corporation Announces Board Resignations CI
Exact Sciences Corporation announced that it has received $266.75 million in funding CI
Sector Update: Health Care Stocks Advance Premarket Monday MT
Exact Sciences Names Aaron Bloomer CFO MT
Chart Exact Sciences Corporation
More charts
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
46.36 USD
Average target price
80.58 USD
Spread / Average Target
+73.82%
Consensus
  1. Stock Market
  2. Equities
  3. EXAS Stock
  4. News Exact Sciences Corporation
  5. Exact Sciences Q1 Net Loss Widens, Revenue Increases; 2024 Revenue Outlook Maintained -- Shares Fall After Hours